Posts Categorized: Uncategorized
Young children and HIV-positive individuals are at high risk of developing tuberculosis (TB) disease following exposure and infection to the Mycobacterium tuberculosis (M. tb) bacteria. In the absence of appropriate preventive therapy, M.tb-infected children under the age of five have a 50% risk of developing TB. More than 90% of children that are exposed to… Read more »
THINK’s work and opening of a new research site at Don MacKenzie hospital was noticed in The Crest Magazine.
In September 2017 Doctor Suzanne Staples left for the Netherlands for 1 year as the recipient of the EDCTP -TDR Clinical Research & Development Fellowship. The aim of the fellowship is to build capacity in African researchers through placement at a European Scientific research organisation. Through this placement fellows learn and understand the operation of… Read more »
It seems only fitting that I share this article shortly after Africa Day (May 25). As put forth by the South Africa Government, “Africa Day presents an opportunity for South Africans to reconnect and recommit themselves in support of all government Africa and a better world.” This year’s Africa Day celebration theme focused on empowering… Read more »
THINK is proud to announce that we are partners of the Stop TB Partnership. As partners of Stop TB, THINK endeavours to endorse the values and principles of the Stop TB Partnership : Support implementation of the Global Plan to Stop TB Be active in the area of TB, sustainable development and related fields and committed… Read more »
On 24 March 1882, Dr. Robert Koch announced that he has discovered the bacterium that causes tuberculosis. It is for this reason that World TB Day is held annually on this day. However, it is not a celebration. We can only celebrate once we have managed to End TB. While in our daily work we… Read more »
A Phase 2 Open-Label Partially Randomized Trial to Evaluate the Efficacy, Safety and Tolerability of combinations of bedaquiline, moxifloxacin, PA-824 and pyrazinamide during 8 weeks of treatment in Adult Subjects with Newly Diagnosed Drug-Sensitive or Multi Drug-Resistant, Smear Positive Pulmonary Tuberculosis. Download the full bulletin here